• Event Details
• Agenda
• CE Information

Topics to Be Discussed

• Overview of the biologic and clinical similarities and differences among the more common indolent and aggressive lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma and Hodgkin lymphoma; patient signs and symptoms at presentation and diagnostic/staging considerations; key patient- and disease-specifc factors affecting the care of patients with different lymphomas
• Incidence, prognoses and treatment options for patients with newly diagnosed and relapsed follicular lymphoma, including commonly used chemotherapy regimens, anti-CD20 antibodies (eg, rituximab), immunomodulatory agents (eg, lenalidomide), EZH2 inhibitors (eg, tazemetostat) and PI3 kinase inhibitors (eg, idelalisib, copanlisib, duvelisib); toxicity profiles of these agents alone and in combination and strategies for management
• Incidence and prognosis of the aggressive lymphoma variant DLBCL; standard and novel treatment approaches for relapsed disease, including polatuzumab vedotin, tafasitamab/lenalidomide, selinexor and CAR (chimeric antigen receptor) T-cell therapies; review of the mechanisms of action, practical challenges in incorporating these agents into the treatment algorithm and unique side effects and amelioration strategies
• Incidence and prognosis of mantle-cell lymphoma; key treatments for relapsed disease, including chemotherapeutic options, BTK (Bruton tyrosine kinase) inhibitors (eg, ibrutinib, acalabrutinib, zanubrutinib) and immunomodulatory agents, and side-effect management strategies; emerging evidence for the efficacy of the Bcl-2 inhibitor venetoclax and its potential role in the treatment armamentarium
• Incidence, prognosis and treatment options for newly diagnosed and relapsed Hodgkin lymphoma: Chemotherapy and the CD30 antibody-drug conjugate brentuximab vedotin (BV); immune checkpoint inhibitors (eg, pembrolizumab, nivolumab); frequency and management of BV-associated peripheral neuropathy and other toxicities
• Newly approved agents: Mechanism of action, efficacy, and incidence, type and management of associated adverse events

Target Audience
These activities have been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lymphomas.

Learning Objectives
Upon completion of each activity, participants should be able to

• Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory (R/R) follicular lymphoma (FL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma, and use this information to enhance decision-making for patients.
• Understand the rationale for the use of lenalidomide in combination with rituximab for newly diagnosed and R/R FL, appraise available data documenting the utility of this regimen and appropriately counsel patients regarding what role, if any, it should play in their care.
• Recognize how prior therapeutic exposure and patient and disease characteristics, including EZH2 mutation status, affect the selection and sequencing of available systemic treatments for R/R FL.
• Appraise the similarities and differences among commercially available Bruton tyrosine kinase inhibitors, and counsel patients with R/R MCL regarding the selection and sequencing of these agents.
• Recall existing and emerging efficacy data from clinical trials of approved and investigational CAR (chimeric antigen receptor) T-cell therapies directed at CD19 for R/R B-cell lymphomas, and identify patients who may be candidates for this approach.
• Understand the FDA-approved indications for polatuzumab vedotin, selinexor and tafasitamab/ lenalidomide for patients with R/R DLBCL, and consider how these agents can be appropriately and safely incorporated into clinical practice.
• Consider available clinical trial data and the scientific rationale for the evaluation of brentuximab vedotin in combination with AVD (doxorubicin/vinblastine/dacarbazine) to discern how this regimen can be optimally incorporated into the front-line management of advanced classical Hodgkin lymphoma.
• Educate patients about the side effects associated with approved therapies commonly used in the management of various forms of lymphoma, and provide preventive strategies to reduce or ameliorate these toxicities.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
Each educational activity for 1 contact hour is provided by RTP.

Each activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for each event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.researchtopractice.com/Webinars/ONS2021/Fall-MTP/Lymphomas/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Goodrich and Ms Klebig have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Ansell – Contracted Research (to Institution): ADC Therapeutics, Affimed, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc, Trillium Therapeutics Inc. Dr Leonard – Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Miltenyi Biotec, Regeneron Pharmaceuticals Inc, Sutro Biopharma; Contracted Research: Epizyme Inc, Genentech Foundation, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from Bristol-Myers Squibb Company, Epizyme Inc, Incyte Corporation, Novartis and Seagen Inc.